Nevertheless, targeting downstream elements in the BCR pathway could result in increased cytotoxicity in vivo as BCRi induce mobilization of CLL cells from the lymph nodes, their survival promoting niches in vivo [29]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.